Absci Corporation

ABS-201 demonstrated a favorable safety profile and an impressive half-life of at least 65 days in Phase 1 trials, supporting infrequent dosing schedules. Guggenheim raised its price target to $15, maintaining a Buy rating, citing ABS-201's strong potential in the underserved androgenetic alopecia and endometriosis markets, with the company projecting over $4.5 billion in peak sales.

H.C. Wainwright's risk-adjusted peak sales estimate for ABS-201 in endometriosis stands at only $549 million — a fraction of Absci's own $4.5 billion projection. Competitive pressure in androgenetic alopecia remains significant, and with proof-of-concept data not expected until early 2027, near-term clinical de-risking is limited.

BTIG initiated coverage with a Buy rating and a $9 price target, specifically highlighting Absci's AI drug platform as a key differentiator. The company's AMD partnership adds further strategic credibility, and with revenue forecast to grow 46.5% per year — far outpacing the broader US market — the platform is seen as a genuine commercial catalyst.

Skepticism about AI's real-world impact on drug discovery keeps Absci's stock heavily underwater from its IPO price. The company's candidates remain in early R&D stages, and the highly speculative nature of AI-driven drug development introduces significant execution risk that the current market cap may not adequately reflect.

H.C. Wainwright raised its price target to $16 following positive Phase 1 data and a strategic equity raise, maintaining a Buy rating. The stock's 265% gain over the past year and a low price-to-book ratio of 1.5 suggest that the market has yet to fully price in the value of Absci's pipeline and strategic partnerships.

Leerink's initiation suggests ABSI stock could be 63% overvalued following its sharp run-up, with a 150% gain over 90 days raising concerns about stretched valuations. Cash reserves of $125.7 million are estimated to last only into H1 2028, and recent at-the-money offering activity signals elevated dilution risk for existing shareholders.